• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    SYSTEMS AND METHODS FOR ASSESSING THE INTEGRITY OF A UTERINE CAVITY. Methods, systems and devices to assess the integrity of a uterine cavity. One method comprises inserting a probe transcervically into a patient's uterine cavity, delivering a flow of fluid (e.g., CO2) through the probe into the uterine cavity, and monitoring the flow rate to characterize the uterine cavity as perforated or not drilled based on a change in flow rate. If the flow rate drops to zero or close to zero, it indicates that the uterine cavity is intact and not perforated. If the flow rate does not fall to zero or close to zero, it indicates that a flow of fluid is leaking through a perforation in the uterine cavity into the uterine cavity or escaping around an occlusion balloon that closes the cervical canal.
    公开号:BR112012011138B1
    申请号:R112012011138-8
    申请日:2010-11-11
    公开日:2020-11-03
    发明作者:Akos Toth
    申请人:Minerva Surgical, Inc；
    IPC主号:
    专利说明:

    References to related requests
    [0001] The present application claims priority of US patent application no. 12 / 616,318 (Prosecutor's dossier 027962-000300US), filed on November 11, 2009, and US patent application number 12 / 616,343 (Prosecutor's dossier 027962-000400US), filed on November 11, 2009, whose full disclosures are incorporated here by way of reference. Background
    [0002] Field of the invention. The present invention relates to electrosurgical methods and devices for global endometrial ablation in a treatment of menorrhagia. More particularly, the present invention relates to the application of radiofrequency current in the endometrial tissue by means of capacitively coupling the current through a thin, expandable dielectric element that encloses an ionized gas.
    [0003] A variety of devices have been developed or proposed for endometrial ablation. Of relevance to the present invention, a variety of radiofrequency ablation devices have been proposed including solid electrodes, balloon electrodes, metallic cloth electrodes and the like. Although often efficient many of the previous electrode designs had one or more deficiencies, such as relatively slow treatment times, incomplete treatments, non-uniform depths of ablation and risk of injury to adjacent organs.
    [0004] For these reasons, it would be desirable to provide systems and methods that allow endometrial ablation using radiofrequency current that is fast, provides controlled depth of ablation and that reduces the risk of injury to adjacent organs. At least some of these objectives will be met by the invention described here.
    [0005] Description of the prior art. US patents nos. 5,769,880; 6,296,639; 6,663,626; and 6,813,520 describe intrauterine ablation devices formed from a permeable mesh that defines electrodes for the application of radiofrequency energy to remove uterine tissue. US patent no. 4,979,948 describes a flask filled with an electrolyte solution to apply radiofrequency current to a mucous layer via capacitive coupling. US 2008/097425, having authored a common invention with the present application, describes the distribution of a pressurized fluid from a liquid medium that carries radio frequency current to the tissue, where the liquid is ignited in a plasma as it passes through orifices flow. US 5,891,134 describes a radiofrequency heater in a closed balloon. US 6,041,260 describes radio frequency electrodes distributed on the outer surface of a balloon that is inflated in a body cavity to be treated. US 7,371,231 and US 2009/054892 describe a conductive balloon with an outer surface that acts as an electrode to perform endometrial ablation. US 5,191,883 describes bipolar heating of a medium in a balloon for thermal ablation. US 6,736,811 and US 5,925,038 show an inflatable conductive electrode. SUMMARY
    [0006] The present invention provides methods, systems and devices for assessing the integrity of a uterine cavity. The uterine cavity can be punctured or otherwise damaged by the transcervical insertion of tubes and instruments into the uterine cavity. If the uterine wall is perforated, it would be preferable to postpone any ablation treatment until the uterine wall is healed. A method of the invention comprises transcervically inserting a probe into a patient's uterine cavity, delivering a flow of a fluid (e.g., CO2) through the probe into the uterine cavity and monitoring the flow rate to characterize the uterine cavity as perforated or unperforated based on a change in flow rate. If the flow rate drops to or near zero, it indicates that the uterine cavity is intact and not perforated. If the flow rate does not drop to zero or close to zero, it indicates that a flow of fluid is leaking through a perforation in the uterine cavity into the uterine cavity or escaping around an occlusion balloon that closes the cervical canal.
    [0007] In modalities, a system for characterizing a patient's uterus is provided, comprising a source of a pressurized flow of a fluid; a lumen connected to the source and configured to deliver fluid from the source to a patient's uterine cavity; a sense of flow to monitor the flow of fluid from the lumen into the uterine cavity; and a controller operatively coupled to the flow meter configured to characterize the uterine cavity as at least one perforated or unperforated based on a change in flow.
    [0008] The controller can, for example, generate a signal if the flow does not fall below a predetermined level to thereby characterize the uterine cavity as perforated. The signal can be at least visual, aural and tactile.
    [0009] The controller in modalities generates a signal if the flow falls below a predetermined level to thereby characterize the uterine cavity as unperforated. The signal can be at least visual, aural and tactile.
    [0010] In modalities, a probe is included that is configured for transcervical insertion into a patient's uterine cavity, and the lumen is mounted on the probe. An expandable element can be carried by the probe to expand in the cervical canal. The expandable element can be, for example, a balloon.
    [0011] The probe may include a working end with an energy distribution surface to remove tissue from the uterine cavity. In embodiments, the energy distribution surface is configured to distribute RF energy to the tissue. The power distribution surface can include at least one electrode coupled to an RF generator. In modalities, the controller is configured to disable the activation of the energy distribution surface if the uterine cavity is characterized as perforated. A cancel mechanism can be provided to cancel the disable mechanism.
    [0012] The controller can also be or is alternatively configured to enable activation of the energy distribution surface if the uterine cavity is characterized as unperforated. In modalities, the controller is configured to automatically activate the energy distribution surface if the uterine cavity is characterized as unperforated.
    [0013] In modalities, the controller is configured to characterize the uterine cavity as at least one perforated or unperforated based on a change in a flow rate. Brief description of the drawings
    [0014] To better understand the invention and see how it can be carried out in practice, some preferred modalities are described below, only as non-limiting examples, with reference to the attached drawings, in which similar reference characters consistently indicate corresponding characteristics in all similar modalities in the attached drawings.
    [0015] Figure 1 is a perspective view of an ablation system corresponding to the invention, including a portable electrosurgical device for endometrial ablation, RF energy source, gas source and controller.
    [0016] Figure 2 is a view of the portable electrosurgical device of figure 1 with a thin, expanded, unfolded dielectric structure.
    [0017] Figure 3 is a block diagram of components of an electrosurgical system corresponding to the invention.
    [0018] Figure 4 is a block diagram of the gas flow components of the electrosurgical system of figure 1.
    [0019] Figure 5 is an enlarged perspective view of the expanded thin-walled dielectric structure, showing a collapsible-expandable frame with the thin dielectric wall in spectrum view.
    [0020] Figure 6 is a partial section view of the expanded thin-walled dielectric structure of Figure 5 showing (i) transformable elements of the foldable-expandable frame that moves the structure between folded and (ii) inflow and outflow lumens gas.
    [0021] Figure 7 is a sectional view of an introducing glove showing several lumens of the introducing glove taken along line 7-7 of figure 6.
    [0022] Figure 8A is an enlarged schematic view of an aspect of a method of the invention illustrating the step of introducing an introducing glove into a patient's uterus.
    [0023] Figure 8B is a schematic view of a subsequent step of retracting the introducer sleeve to expose a folded thin-walled dielectric structure and internal frame in the uterine cavity.
    [0024] Figure 8C is a schematic view of subsequent steps of the method, including (i) activating the inner frame to move the folded thin-walled dielectric structure to an expanded configuration, (ii) inflating a cervical seal balloon carried in the sleeve introducer, and (iii) trigger gas flows and apply RF energy to simultaneously ionize the gas in the inner chamber and cause capacitive current coupling through the thin-walled dielectric structure to cause ohmic heating in the tissue involved indicated by current flow pathways.
    [0025] Figure 8D is a schematic view of subsequent steps of the method, including: (i) advancing the introducer sleeve over the thin-walled dielectric structure to fold it into an inner hole shown in spectrum view, and ( ii) remove the introducing glove and dielectric structure from the uterine cavity.
    [0026] Figure 9 is a cut-away perspective view of an alternative expanded thin-walled dielectric structure similar to that of Figures 5 and 6 and shows an alternative electrode configuration.
    [0027] Figure 10 is an enlarged sectional view of a portion of the expanded thin-walled dielectric structure of figure 9 showing the electrode configuration.
    [0028] Figure 11 is a schematic view of a patient's uterus representing a method corresponding to the invention including providing a flow of a fluid medium into the uterine cavity and monitoring the flow rate to characterize the patient's uterine cavity as intact and not perforated.
    [0029] Figure 12 is a perspective view of the ablation device in Figures 1-2 with a subsystem to check the integrity of a uterine cavity.
    [0030] Figure 13 represents a block diagram of a subsystem of the invention to supply and monitor a flow of fluid into the patient's uterine cavity.
    [0031] Figure 14 represents a diagram that indicates the steps of an algorithm to provide and monitor a flow of fluid into the patient's uterine cavity. Detailed Description
    [0032] In general, an electrosurgical ablation system is described here that comprises an elongated introducer element to access a patient's uterine cavity with a working end that unfolds an expandable thin-walled dielectric structure containing an electrically non-conductive gas as a dielectric . In one embodiment, an inner chamber of the thin-walled dielectric structure contains a circulating neutral gas like argon. An RF energy source provides current that is coupled to the flow of neutral gas by a first polarity electrode disposed in the inner chamber and a second polarity electrode outside the working end. The gas flow, which is converted into a conductive plasma by an electrode array, functions as a switching mechanism that allows current flow to the endometrial tissue involved only when the voltage through the combination of the gas, thin-walled dielectric structure and the involved tissue reach a limit that causes capacitive coupling through thin-walled dielectric material. By coupling capacitively current to the fabric in this way, the system provides a substantially uniform fabric effect across the fabric in contact with the expanded dielectric structure. In addition, the invention allows the neutral gas to be created concurrently with the capacitive current coupling to the fabric.
    [0033] In general, this disclosure can use the terms "plasma", "conductive gas" and "ionized gas" interchangeably. A plasma consists of a state in which electrons in a neutral gas are extracted or "ionized" from its molecules or atoms. Such plasmas can be formed by applying an electric field or by elevated temperatures. In a neutral gas, electrical conductivity is nonexistent or very low. Neutral gases act as a dielectric or isolated until the electric field reaches a break value, releasing electrons from atoms in an avalanche process thereby forming a plasma. Such a plasma provides moving electrons and positive ions, and acts as a conductor that supports electrical currents and can form a spark or arc. Due to their lower mass, electrons in a plasma accelerate more quickly in response to an electric field than the heavier positive ions, and consequently carry the volume of the current.
    [0034] Figure 1 represents a modality of an electrosurgical ablation system 100 configured for endometrial ablation. System 100 includes a portable apparatus 105 with a close handle 106 molded to be held in a human hand which is coupled to an elongated introducing sleeve 110 having a geometric axis 111 that extends to a distal end 112. Introducing sleeve 110 can be manufactured from a thin-walled plastic, composite, ceramic or metal in a round or oval cross section with a larger diameter or geometric axis ranging from approximately 4 mm to 8 mm at least in a distal portion of the glove that accesses the uterine cavity. Cable 106 is made of an electrically insulating material such as molded plastic with a pistol grip having first and second portions, 114a and 114b, which can be compressed towards each other to rotate an elongated transformable sleeve 115 which is housed in a hole 120 in the elongated introducer sleeve 110. By driving the first and second cable portions, 114a and 114b, a working end 122 can be unfolded from a first retracted position (figure 1) in the distal portion of hole 120 in the introducer sleeve 110 for an extended position as shown in figure 2. In figure 2, it can be seen that the first and second cable portions, 114a and 114b, are in a second driven position with the working end 122 unfolded from hole 120 in the introducer sleeve 110.
    [0035] Figures 2 and 3 show that the ablation system 100 includes an RF 130A power source and RF 130B controller in a control unit 135. The RF 130A power source is connected to the portable device 105 via a flexible conduit 136 with a plug-in connector 137 configured with a gas inflow channel, a gas outflow channel, and first and second electrical wires to connect to the receiving connector 138 on the control unit 135. The control unit 135, as will be further described below in figures 3 and 4, further comprising a source of neutral gas inflow 140A, gas flow controller 140B and optional negative pressure or vacuum source 145 to provide controlled gas inflows and gas outflows to and from the working end 122. The control unit 135 further includes a balloon filler source 148 for inflating an expandable seal balloon 225 carried in the introducer sleeve 110 as further described below.
    [0036] With reference to figure 2, the working end 122 includes a thin, flexible wall structure or element 150 of a dielectric material which when expanded has a triangular shape configured to contact the patient's endometrial lining which is targeted for ablation. In an embodiment as shown in figures 2, 5 and 6, the dielectric structure 150 comprises a thin-walled material such as silicone with a fluid-tight inner chamber 152.
    [0037] In one embodiment, a foldable-expandable frame assembly 155 is arranged in the inner chamber. Alternatively, the dielectric structure can be expanded by a neutral gas without a frame, but the use of a frame offers several advantages. First, the uterine cavity is flattened with the opposite walls in contact with each other. The expansion of a balloon-like element can cause unwanted pain or spasms. For this reason, a flat structure that is expanded by a frame is best suited for deployment in the uterine cavity. Second, in embodiments of the present invention, the neutral gas is converted into a conductive plasma at a very low pressure controlled by gas inflows and gas outflows - so that any pressurization of a balloon-like element with the neutral gas can exceed a desired pressure range and would require complex controls of gas inflows and gas outflows. Third, as described below, the frame provides an electrode for contact with the neutral gas in the inner chamber 152 of the dielectric structure 150, and the frame 155 extends into all regions of the inner chamber to ensure electrode exposure to all neutral gas and plasma regions. Frame 155 can be constructed of any flexible material with at least portions of the frame acting as spring elements to move the thin-walled structure 150 from a folded configuration (figure 1) to an expanded, unfolded configuration (figure 2) in uterine cavity of a patient. In one embodiment, frame 155 comprises stainless steel elements 158a, 158b and 160a and 160b that function similar to laminated springs. The frame can be a stainless steel like 316 SS, 17A SS, 420 SS, 440 SS or the frame can be a NiTi material. The frame preferably extends along a single plane, remains thin across the plane, so that the frame can expand into the uterine cavity. The frame elements can have a thickness ranging from approximately 0.005 ”to 0.025”. As can be seen in Figures 5 and 6, the close ends 162a and 162b of the spring elements 158a, 158b are fixed (for example, by welds 164) to the distal end 165 of the sleeve element 115. The close ends 166a and 166b of the spring elements 160a, 160b are welded to the distal portion 168 of a secondary transformable sleeve 170 that can be extended from hole 175 in transformable sleeve 115. Secondary transformable sleeve 170 is dimensioned for a loose fit in hole 175 to allow flow of gas at hole 175. Figures 5 and 6 further illustrate the distal ends 176a and 176b of the spring elements 158a, 158b are welded to the distal ends 178a and 178b of the spring elements 160a and 160b to thereby provide a frame 155 that can be moved from a linear shape (see figure 1) to an expanded triangular shape (figures 5 and 6).
    [0038] As will be further described below, hole 175 in sleeve 115 and hole 180 in secondary transformable sleeve 170 function as gas outflow and gas inflow lumens, respectively. It should be recognized that the gas inflow lumen may comprise any single lumen or plurality of lumens in glove 115 or glove 170 or other glove, or other parts of the frame 155 or at least one gas flow lumen can be formed on a wall of dielectric structure 150. In figures 5, 6 and 7 it can be seen that gas inflows are supplied through hole 180 in sleeve 170, and gas flows are provided in hole 175 of sleeve 115. However, inflows and effluxes can also be inverted between holes 175 and 180 of the various gloves. Figures 5 and 6 further show that a rounded damping element 185 is provided at the distal end of sleeve 170 to ensure that no sharp edges of the distal end of sleeve 170 can contact the interior of the thin dielectric wall 150. In one embodiment, the damping element 185 is silicone, but it could also comprise a rounded metal element. Figures 5 and 6 also show that a plurality of gas inflow holes 188 can be provided along a length of sleeve 170 in chamber 152, as well as a hole 190 at the distal end of sleeve 170 and damping element 185. The view in section of figure 7 it also shows the gas flow passages inside the introducer sleeve 110.
    [0039] It can be understood from figures 1, 2, 5 and 6 that the activation of the first and second cable portions, 114a and 114b, (i) initially causes movement of the glove assembly 115 and 170 in relation to the hole 120 of the introducer glove 110, and (ii) secondly causes extension of the glove 170 from the hole 175 in the glove 115 to expand the frame 155 in the triangular shape of figure 5. The dimensions of the triangular shape are suitable for the uterine cavity of a patient, and, for example, may have an axial length A ranging from 4 to 10 cm and a maximum width B at the distal end ranging from approximately 2 to 5 cm. In one embodiment, the thickness C of the thin-walled structure 150 can be 1 to 4 mm as determined by the dimensions of the spring elements 158a, 158b, 160a and 160b of the frame assembly 155. It should be recognized that the frame assembly 155 it may comprise round wire elements, flat spring elements, of any suitable metal or polymer that can provide opening forces to move the thin-walled structure 150 from a folded configuration to an expanded configuration within the patient's uterus. Alternatively, some elements of the frame 155 can be spring elements and some elements can be flexible without inherent spring characteristics.
    [0040] As will be described below, the working end modality of figures 2, 5 and 6 has a thin-walled structure 150 that is formed of a dielectric material such as silicone that allows capacitive current coupling to the fabric involved while assembling frame 155 provides structural support for positioning the thin-walled structure 150 against the fabric. In addition, inflows of gas into the inner chamber 152 of the thin-walled structure can assist in supporting the dielectric wall in order to contact endometrial tissue. The thin-walled dielectric structure 150 may be free of attachment to the frame assembly 155, or may be attached to an outwardly facing portion or portions of the frame elements 158a and 158b. the near end 182 of the thin-walled structure 150 is connected to the outside of the distal end of the sleeve 115 to thereby provide a sealed, fluid-tight inner chamber 152 (figure 5).
    [0041] In one embodiment, the gas inflow source 140A comprises one or more compressed gas cartridges that communicate with flexible conduit 136 through plug connector 137 and receiving connector 138 on control unit 135 (figures 1- two). As can be seen in figures 5-6, gas inflows from source 140A flow through hole 180 in sleeve 170 to open ends 188 and 190 in it to flow into inner chamber 152. A vacuum source 145 is connected through conduit 136 and connector 137 to allow the flow of gas to flow through the inner chamber 152 of the thin-walled dielectric structure 150. In figures 5 and 6, it can be seen that gas flows communicate with the vacuum source 145 through the open end 200 of hole 175 in sleeve 115. With reference to figure 5, it can be seen that the frame elements 158a and 158b are configured with a plurality of openings 202 to allow gas flows through all the interior portions of the frame elements , and thereby inflows of gas from open ends 188, 190 into bore 180 are free to circulate through inner chamber 152 to return to an efflux path through open end 200 of bore 175 of sleeve 115. As will be described below (see figures 3-4), the 140A gas inflow source is connected to a 140B gas flow or flow controller that controls a 205 pressure regulator and also controls a 145 vacuum source. which is adapted to assist in the circulation of gas. It should be recognized that the frame elements can be configured with openings, notched edges or any other configurations that allow effective circulation of a gas through the inner chamber 152 of the thin wall structure 150 between the inflow and outflow passages.
    [0042] Turning now to the electrosurgical aspects of the invention, figures 5 and 6 illustrate electrodes of opposite polarity of the system 100 that are configured to convert a flow of neutral gas in chamber 152 into a plasma 208 (figure 6) and allow capacitive coupling current through a wall 210 of the thin-walled dielectric structure 150 to the endometrial tissue in contact with the wall 210. Electrosurgical methods of capacitively coupling RF current through a plasma 208 and dielectric wall 210 are described in patent application US 12 / 541,043; filed on August 13, 2009 (in Prosecutor's dossier 027980-000110US) and US order number 12 / 541,050 (in Prosecutor's dossier 027980-000120US), referenced above. In figures 5 and 6, the first polarity electrode 215 is inside the inner chamber 152 for contacting the neutral gas flow and comprises the frame assembly 155 which is made of an electrically conductive stainless steel. In another embodiment, the first polarity electrode can be any element disposed in the inner chamber 152, or extendable into the inner chamber 152. The first polarity electrode 215 is electrically coupled to sleeves 115 and 170 that extend through the introducing sleeve 110 to cable 106 and conduit 136 and is connected to a first pole of the RF source power source 130A and controller 130B. A second polarity electrode 220 is external to the inner chamber 152 and in one embodiment the electrode is separated from the wall 210 of the thin-walled dielectric structure 150. In one embodiment as shown in Figures 5 and 6, the second polarity electrode 220 comprises a surface element of an expandable balloon element 225 carried by the introducer sleeve 110. The second polarity electrode 220 is coupled by a wire (not shown) that extends through the introducer sleeve 110 and conduit 136 to a second well of the RF source 130A. It should be recognized that the second polarity electrode 220 can be positioned on sleeve 110 or can be attached to surface portions of the expandable thin-walled dielectric structure 150, as will be described below, to provide appropriate contact with body tissue to allow electrosurgical ablation of the method of the invention. The second polarity electrode 220 may comprise a thin conductive metallic film, thin metal wires, a flexible conductive polymer or a positive polymeric temperature coefficient material. In an embodiment shown in figures 5 and 6, the expandable element 225 comprises a flexible thin-walled balloon having a length of approximately 1 cm to 6 cm that can be expanded to seal the cervical canal. The balloon 225 may be filled with a gas or liquid by any filling source 148, and may comprise a syringe mechanism controlled manually or by the control unit 135. The balloon filling source 148 is in fluid communication with a lumen of filling 228 in the introducer sleeve 110 which extends to a balloon filling chamber 225 (see figure 7).
    [0043] With reference again to figure 1, the control unit 135 can include a display 230 and touch screen or other controls 232 to define and control operational parameters such as treatment time intervals, treatment algorithms, gas flows, energy levels and the like. Gases suitable for use in the system include argon, other noble gases and mixtures thereof. In one embodiment, a foot switch 235 is coupled to the control unit 134 to drive the system.
    [0044] The square diagrams in figures 3 and 4 schematically represent the system 100, subsystems and components that are configured for an endometrial ablation system. In the square diagram of figure 3, it can be seen that the RF power source 130A and circuitry are controlled by a controller 130B. the system may include feedback control systems that include signals referring to plasma operating parameters in the inner chamber 152 of the dielectric structure 150. For example, feedback signals may be provided from at least one temperature sensor 240 in the inner chamber 152 of the structure dielectric 150, from a pressure sensor inside or in communication with the inner chamber 152 and / or a gas flow rate sensor in an inflow or outflow channel of the system. Figure 4 is a schematic block diagram of the flow control components referring to the flow of gas media through system 100 and portable device 105. It can be seen that a pressurized gas source 140A is connected to a downstream pressure regulator 205, a proportional inflow valve 246, flow meter 248 and normally closed solenoid valve 250. Valve 250 is actuated by the system operator who then allows a flow of neutral gas from the gas source 140A to circulate through flexible conduit 136 and device 105. The gas outflow side of the system includes a normally open solenoid valve 260, proportional outflow valve 262 and flow meter 264 that communicate with the source or vacuum pump 145. The gas can be discharged into the environment or into a containment system. A temperature sensor 270 (for example, thermocouple) is shown in figure 4 which is configured to monitor the temperature of the efflux gases. Figure 4 further represents an optional subsystem 275 comprising a vacuum source 280 and solenoid valve 285 coupled to controller 140B to draw steam from a uterine cavity 302 outside the dielectric structure 150 during a treatment interval. As can be understood from figure 4, the flow passage from the uterine cavity 302 can be direct hole 120 in glove 110 (see figures 2, 6 and 7) or another lumen in a wall of glove 110 can be provided .
    [0045] Figures 8A-8D schematically illustrate a method of the invention in which (i) the thin-walled dielectric structure 150 is deployed in a patient's uterus and (ii) RF current is applied to a volume of neutral gas contained in the chamber interior 152 to create a plasma 208 in the chamber at the same time and capacitively coupling current through the thin dielectric wall 210 to apply ablation energy to the endometrial lining to perform global endometrial ablation.
    [0046] More particularly, figure 8A illustrates the uterus of a patient 300 with uterine cavity 302 surrounded by endometrium 306 and myometrium 310. The external cervical bone 312 is the opening of the cervix 314 into the vagina 316. The internal opening or osss 320 is a region of the cervical canal that opens into the uterine cavity 302. Figure 8A represents a first step in a method of the invention in which the physician introduced a distal portion of the glove 110 into the uterine cavity 302. The physician can smoothly advance the glove 110 until its distal tip contacts the bottom 324 of the uterus. Before inserting the device, the physician can optionally insert a sound instrument into the uterine cavity to determine uterine dimensions, for example, from the inner bone 320 to the bottom 324.
    [0047] Figure 8B illustrates a subsequent step of a method of the invention in which the physician begins to drive the first and second cable portions 114a and 114b, and the introducer sleeve 110 retracts in the next direction to expose the folded frame 155 and structure thin-walled 150 in the uterine cavity 302. Glove 110 can be retracted to expose an axial length selected from the thin-walled dielectric structure 150, which can be determined by markings 330 on glove 115 (see figure 1) that indicate axial displacement of sleeve 115 in relation to sleeve 170 and thereby directly related to the length of unfolded thin wall structure 150. Figure 2 represents the cable portions 115a and 114b fully approximated in this way by unfolding the thin wall structure to its maximum length.
    [0048] Figure 8C illustrates several subsequent steps of a method of the invention. Figure 8C first represents the physician continuing to drive the first and second cable portions, 114a and 114b, which further drive frame 155 (see figures 5-6) to expand frame 155 and thin-walled structure 150 to a shape triangular unfolded to contact the patient's endometrial lining 306. The physician can slightly rotate and move the expansion dielectric structure 150 back and forth as the structure is opened to ensure that it is open to the desired point. In carrying out this step, the physician can drive portions of cable 114a and 114b, a selected degree that causes a selected length of sleeve displacement 170 relative to sleeve 115 which, in turn, opens frame 155 to a selected degree. The actuation selected from glove 170 in relation to glove 115 also controls the length of the dielectric structure unfolded from glove 110 into the uterine cavity. In this way, the thin-walled structure 150 can be deployed in the uterine cavity to a selected length, and the elastic strength of the frame elements 155 will open the structure 150 to a triangular shape selected to contact or surround the endometrium 306. In one embodiment, the expandable thin-walled structure 150 is induced in direction and held in an open position by the elastic force of the frame elements 155. In the embodiment shown in figures 1 and 2, cable 106 includes a locking mechanism with finger-operated cursors 332 in each side of the cable that engages a locking locking element against a notch in housing 333 coupled to the introducer sleeve 110 (figure 2) to lock the sleeves 115 and 170 in relation to the introducer sleeve 110 to maintain the thin wall dielectric structure 150 in the selected open position.
    [0049] Figure 8C further illustrates the physician expanding the expandable balloon structure 225 from the filling source 148 to thereby provide an elongated sealing element to seal the neck 314 out of the inner bone 320. After unfolding the structure of thin wall 150 and balloon 225 in the neck 314, the system 100 is ready for the application of RF energy to remove endometrial tissue 306. Figure 8C next represents the activation of the system 100, for example, by activating the foot switch 235, which initiates a flow of neutral gas from source 140A into the inner chamber 152 of the thin-walled dielectric structure 150. Contemporary with, or after a selected delay, the activation of the system distributes RF energy to the electrode array that includes the first electrode polarity 215 (+) of frame 155 and second polarity electrode 220 (-) which is carried on the surface of the expandable balloon element 225. The RF energy distribution is it will instantly lift the neutral gas in the inner chamber 152 into conductive plasma 208 which in turn results in capacitive current coupling through the dielectric wall 210 of the thin wall structure 150 resulting in ohmic heating of the tissue involved. Figure 8C schematically illustrates the multiplicity of RF 350 current paths between the plasma 208 and the second polarity electrode 220 through the dielectric wall 210. By this method, it was found that ablation depths from three mm to six mm or more can be performed very quickly, for example, in 60 seconds to 120 seconds depending on the selected voltage and other operational parameters. In operation, the voltage at which the inflow of neutral gas, such as argon, becomes conductive (that is, converted in part to a plasma) depends on several factors controlled by the 130B and 140B controllers, including the neutral gas pressure, volume of the inner chamber 152, the gas flow rate through the chamber 152, the distance between the electrode 210 and the inner surfaces of the dielectric wall 210, the dielectric constant of the dielectric wall 210 and the selected voltage applied by the RF source 130, all of which can be optimized by experimentation. In one embodiment, the gas flow rate can be in the range of 5 ml / s to 50 ml / s. the dielectric wall 210 may comprise a silicone material having a thickness ranging from 0.005 ”to 0.015 and having a relative permittivity in the range of 3 to 4. The gas can be argon supplied in a pressurized cartridge that is commercially available. The pressure in the inner chamber 152 of dielectric structure 150 can be maintained between 14 psia and 15 psia with negative or zero differential pressure between the gas inflow source 140A and the vacuum or negative pressure source 145. The controller is configured to maintain the pressure in the inner chamber in a range that varies by less than 10% or less than 5% of a target pressure. The RF 130A power source can have a frequency of 450 to 550 KHz, and electrical power can be supplied in the range of 600 Vrms to approximately 1200 Vrms and approximately 0.2 Amps to 0.4 Amps and an effective power of 40W to 100W . in one method, control unit 135 can be programmed to distribute RF energy for a pre-selected time interval, for example, between 60 seconds and 120 seconds. One aspect of a treatment method corresponding to the invention is to remove endometrial tissue with RF energy to elevate the endometrial tissue to a temperature greater than 45 degrees Celsius for a period of time sufficient to remove tissue to a depth of at least 1 mm. Another aspect of the endometrial ablation method is to apply radiofrequency energy to raise endometrial tissue to a temperature greater than 45 degrees Celsius without damaging the myometrium.
    [0050] Figure 8D illustrates a final step in the method in which the doctor deflates the expandable balloon element 225 and then extends the sleeve 110 distally by driving the cables 114a and 114b to fold the frame 155 and then retract the assembly of the uterine cavity 302. Alternatively, the unfolded working end 122 as shown in figure 8C can be removed in the direction close to the uterine cavity where the frame 155 and thin-walled structure 150 will bend as they are pulled through the cervix. Figure 8D shows the completed ablation with the removed endometrial tissue indicated in 360.
    [0051] In another embodiment, the system may include an electrode array in the cable 106 or in the gas inflow channel to pre-ionize the neutral gas flow before reaching the inner chamber 152. For example, the inflow channel of gas can be configured with electrodes of opposite polarity axially or radially separated configured to ionize the inflow of gas. Such electrodes would be connected in separate circuits to an RF source. The first and second electrodes 215 (+) and 220 (-) described above would operate as described above to supply the current that is capacitively coupled to the tissue through the walls of the dielectric structure 150. In all other respects, the system and method would function as described above.
    [0052] Turning now to figures 9 and 10, an alternating working end 122 with thin-walled dielectric structure 150 is shown. In this embodiment, the thin-walled dielectric structure 150 is similar to that of figures 5 and 6 except that the second electrode of polarity 220 'which is outside the inner chamber 152 is disposed on a surface portion 370 of the thin-walled dielectric structure 150. In this embodiment, the second polarity electrode 220 'comprises a conductive thin film material, such as gold, which is bonded to the outside of thin wall material 210 along two side sides 354 of dielectric structure 150. It must be recognized that the second The polarity electrode can comprise one or more conductive elements disposed outside the wall material 210, and can extend axially, or transversely with respect to the geometric axis 111 and can be a single element or multiple elements. In an embodiment shown in more detail in figure 10, the second electrode of polarity 220 'can be attached to another slippery layer 360, such as a polyimide film, for example, KAPTON®. The polyimide tape extends around the side sides 354 of the dielectric structure 150 and provides protection to the wall 210 when it is advanced from or removed into hole 120 in sleeve 110. In operation, the RF distribution method using the modality of the figures 9 and 10 is the same as described above, with the RF current being capacitively coupled from plasma 208 through wall 210 and endometrial tissue to the second polarity electrode 2201 to cause ablation.
    [0053] Figure 9 also shows an optional temperature sensor 390, such as a thermocouple, transported outside the dielectric structure 150. In a method of use, the control unit 135 can acquire temperature feedback signals from at least one sensor 390 to modulate or terminate RF energy distribution, or modulate gas flows in the system. In a related method of the invention, the control unit 135 can acquire temperature feedback signals from the temperature sensor 240 in the inner chamber 152 (figure 6) to modulate or terminate RF energy distribution or modulate gas flows in the system.
    [0054] In another embodiment of the invention, figures 11-14 represent systems and methods for assessing the integrity of the uterine cavity that can be punctured or otherwise damaged by the transcervical insertion of probes and instruments into a uterine cavity. If the uterine wall is perforated, it would be preferable to postpone any ablation treatment until the uterine wall is healed. A method of the invention comprises transcervically inserting a probe into a patient's uterine cavity, delivering a flow of a fluid (e.g., CO2) through the probe into the uterine cavity and monitoring the flow rate to characterize the uterine cavity as perforated or unperforated based on a change in flow rate. If the flow rate drops to or near zero, it indicates that the uterine cavity is intact and not perforated. If the flow rate does not drop to zero or close to zero, it indicates that a flow of fluid is leaking through a perforation in the uterine cavity 302 into the uterine cavity or escaping around an occlusion balloon that closes the cervical canal .
    [0055] In figure 11, it can be seen as a source of pressurized fluid 405 and controller 410 to control and monitor flow is in fluid communication with lumen 120 of introducer sleeve 110 (see figure 7). In one embodiment, the fluid source may be a pressurized cartridge containing CO2 or another biocompatible gas. In figure 12, it can be seen that the fluid source 405 communicates with a flexible conduit 412 which is connected to a "tail" pipe connector 414 extending out from the cable 106 of the portable probe. A tubing inside the cable component 114a provides a flow passage 415 to lumen 120 in the introducer sleeve. In another embodiment, the fluid source 405 and flexible conduit 408 can be integrated into the conduit 136 of figure 1.
    [0056] In figure 11, it can be seen that the fluid flow is introduced into the uterine cavity 302 after the balloon 225 in the cervical canal has been filled and after the working end and dielectric structure 150 have been expanded to its triangular shape to occupy the uterine cavity. In this way, the CO2 gas flows around the outer surfaces of the expanded dielectric structure 150 to fill the uterine cavity. Alternatively, the CO2 flow can be supplied after the balloon 225 in the cervical canal is filled, but before the expansion of the dielectric structure 150.
    [0057] Figure 13 is a block diagram that schematically represents the components of subsystem 420 that supplies the CO2 flow to and through the portable probe 105. It can be seen that the pressurized fluid source 405 communicates with a pressure regulator at downstream 422, a proportional valve 424, flow meter 440, normally closed solenoid valve 450 and one-way valve 452. The valve 450 after activation by the system operator allows a flow of CO2 gas from the source 405 at a rate of predetermined flow and pressure through the subsystem and into the uterine cavity 302.
    [0058] In a modality of the method of operation, the doctor activates the system and electronically opens the valve 450 that can supply a flow of CO2 through the system. Controller 410 monitors the sensor or flow meter 440 for an interval that can vary from 1 second to 60 seconds, or 5 seconds to 30 seconds to determine the change in flow rate and / or change in flow rate. In one embodiment, the flow sensor comprises a Honeywell Mass Air Flow Sensor series AWM5000, for example, Model AWM5101, which measures flows in mass flow units. In one embodiment, the initial flow rate is between 0.05 slpm (standard liters per minute) and 2.0 slpm, or between 0.1 slpm and 0.2 slpm. Controller 410 includes a microprocessor or programmable logic device that provides a feedback signal from the flow sensors indicating (i) that the flow rate has dropped to zero or close to zero to thereby characterize the uterine cavity as unperforated, or (ii) that the flow rate has not dropped to a predetermined threshold level in a predetermined time interval to thereby characterize the uterine cavity as perforated or that the occlusion balloon 225 fails or unfolds so that the cervical canal is not closed. In one embodiment, the threshold level is 0.05 slpm to characterize the uterine cavity as unperforated. In this mode, the controller provides a signal indicating an unperforated uterine cavity if the flow falls below 0.05 slpm between the fifth second of the flow and the flow waiting time, which can be, for example, 30 seconds.
    [0059] Figure 14 represents aspects of an algorithm used by controller 410 to perform an integrity check of the uterine cavity, with the first step comprising activating a foot switch or hand switch. After starting, a timer is started for 1 to 5 seconds to determine that a fluid source 405 is capable of providing a fluid flow, which can be verified by a pressure sensor between the source 405 and pressure regulator 422. If none flow is detected, an error signal is provided, such as a visual display signal on control unit 135 (figure 1).
    [0060] As can be understood from figure 14, after the 405 fluid source is checked, the controller opens the supply solenoid valve 450 and a timer is started for a test interval of 1 to 5 seconds to ensure flows flow through subsystem 420 of figure 13, with either or both a flow meter 440 or a pressure sensor. At the same time that valve 450 is opened, a timer is started for a 30 second cavity integrity test interval. Controller 410 monitors flow meter 440 and provides a signal characterizing the uterine cavity as unperforated if, at any time after the initial 5-second verification interval, and before the end of the waiting period (for example, the waiting time of 30 seconds), the flow rate drops below a minimum threshold rate, in one mode, to below 0.05 slpm. If the interval passes after 30 seconds and the flow rate does not fall below this limit, then a signal is generated that characterizes that the uterine cavity is perforated. This signal may also indicate a failure of the 225 occlusion balloon.
    [0061] With reference to figure 14, in one embodiment, in response or otherwise as a result of the signal that the uterine cavity is not punctured, controller 410 can automatically enable and activate the RF ablation system described above to perform a ablation procedure. Controller 410 can provide a time interval of 1 to 15 seconds to allow CO2 gas to bleed from the uterine cavity 302 before activating the RF energy distribution. In another embodiment, the endometrial ablation system may include optional subsystem 275 for discharging fluids or gas from the uterine cavity during an ablation treatment (see figure 4 and associated text). This subsystem 275 can be activated to discharge CO2 from the uterine cavity 302 that includes opening solenoid valve 285 shown in figure 4.
    [0062] The system can also include a cancellation to repeat the cavity integrity check, for example, after evaluation and further unfolding of the occlusion balloon 225.
    [0063] Although specific embodiments of the present invention have been described in detail above, it will be understood that this description is for illustration purposes only and the above description of the invention is not exhaustive. Specific features of the invention are shown in some drawings and not in others, and this is for convenience only and any feature can be combined with another according to the invention. Several variations and alternatives will be evident to a person with common knowledge in the art. Such alternatives and variations are intended to be included in the scope of the claims. Specific features that are presented in dependent claims can be combined and are within the scope of the invention. The invention also encompasses modalities as if the dependent claims are alternatively written in a multiple dependent claim format with reference to other independent claims.
    权利要求:
    Claims (6)
    [0001]
    1. System (300) for performing a procedure on a patient's gynecological tract, characterized by the fact that it comprises: an ablation device; first and second expandable elements carried by the device, the expandable elements having fluid-tight walls; a source (140A, 405) of a pressurized flow of a fluid; a passage in the device, connected to the source, and configured to distribute the fluid from the source (405) to a region surrounding a device exterior when the expandable elements are expanded into or near at least a portion of the cervical canal and the uterine cavity. a patient; a flow sensor for measuring a flow rate of the fluid in the passage; and a controller (410) operatively coupled to the flow sensor (440) and the source, the controller being configured to (1) initiate a flow of fluid from the source through the passage, (2) measure the flow rate using the flow sensor flow, and (3) determining whether the measured flow rate falls below a predetermined minimum level within a predetermined period of time ranging from 1 second to 60 seconds.
    [0002]
    2. System according to claim 1, characterized by the fact that the controller (140B, 410) is configured to generate a signal indicating that the uterine cavity has a perforation if the flow rate fails to fall below this predetermined minimum level within said time period.
    [0003]
    3. System according to claim 1, characterized by the fact that the controller (140B, 410) is configured to generate a signal indicating that the uterine cavity is not punctured if the flow rate falls below said predetermined minimum level within of said period of time.
    [0004]
    4. System, according to claim 1, characterized by the fact that the ablation device carries at least one electrode coupled to an RF generator.
    [0005]
    5. System according to claim 4, characterized by the fact that the controller is configured to disable the activation of at least one electrode if the flow rate fails to drop below said predetermined minimum level within said period of time.
    [0006]
    6. System according to claim 4, characterized by the fact that the controller is configured to automatically activate at least one electrode if the flow rate falls below said predetermined minimum level within said time period.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012011138B1|2020-11-03|system to perform a procedure on a patient's gynecological tract
    US11191588B2|2021-12-07|Methods for evaluating the integrity of a uterine cavity
    US10456194B2|2019-10-29|System and method for endometrial ablation
    US10932712B2|2021-03-02|Methods and systems for evaluating the integrity of a uterine cavity
    US9050102B2|2015-06-09|System and method for endometrial ablation
    US8939971B2|2015-01-27|System and method for endometrial ablation
    US10722298B2|2020-07-28|Systems and methods for endometrial ablation
    US8926629B2|2015-01-06|Systems and methods for endometrial ablation
    US11020045B2|2021-06-01|Systems and methods for evaluating the integrity of a uterine cavity
    US20170128127A1|2017-05-11|Gynecological treatment methods
    同族专利:
    公开号 | 公开日
    US8394037B2|2013-03-12|
    EP2498679B1|2018-10-17|
    CA2780602A1|2011-05-19|
    US20130304055A1|2013-11-14|
    CA2780602C|2016-10-04|
    WO2011060191A1|2011-05-19|
    EP2498679A4|2014-04-02|
    US20130310705A1|2013-11-21|
    EP2498679A1|2012-09-19|
    US9775542B2|2017-10-03|
    US20110112433A1|2011-05-12|
    US8343078B2|2013-01-01|
    CN102647943B|2015-09-02|
    CN102647943A|2012-08-22|
    US20110112432A1|2011-05-12|
    BR112012011138A2|2016-07-05|
    US20130281880A1|2013-10-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3247841A|1961-05-29|1966-04-26|Galen B Cook|Diagnostic method|
    US3227154A|1962-05-11|1966-01-04|Galen B Cook|Diagnostic bag with impressionable outer surface and method of using it|
    US3313291A|1963-11-06|1967-04-11|Sigmamotor Inc|Apparatus for the injection of radioopaque liquid in angiography|
    US4198981A|1978-03-27|1980-04-22|Manfred Sinnreich|Intrauterine surgical device|
    US4325387A|1979-12-17|1982-04-20|American Home Products Corporation|Sealing apparatus for intrauterine pressure catheter and the like|
    US4349033A|1980-11-06|1982-09-14|Eden Robert D|Intrauterine catheter|
    DE3300694A1|1983-01-11|1984-08-09|Siemens AG, 1000 Berlin und 8000 München|BIPOLAR ELECTRODE FOR MEDICAL APPLICATIONS|
    US5184619A|1986-11-10|1993-02-09|Peritronics Medical, Inc.|Intrauterine pressure and fetal heart rate sensor|
    US4944307A|1988-08-22|1990-07-31|The Hon Group|Intrauterine catheter|
    US5191883A|1988-10-28|1993-03-09|Prutech Research And Development Partnership Ii|Device for heating tissue in a patient's body|
    US4966161A|1989-03-31|1990-10-30|Utah Medical Products|Apparatus for continuously measuring intracompartmental pressure within a body cavity|
    US4979948A|1989-04-13|1990-12-25|Purdue Research Foundation|Method and apparatus for thermally destroying a layer of an organ|
    DE3922746C1|1989-07-11|1990-08-23|Richard Wolf Gmbh, 7134 Knittlingen, De|
    US5242390A|1991-05-03|1993-09-07|Goldrath Milton H|Endometrium coagulating surgical method for thermal destruction of the endometrium|
    US5443470A|1992-05-01|1995-08-22|Vesta Medical, Inc.|Method and apparatus for endometrial ablation|
    US5277201A|1992-05-01|1994-01-11|Vesta Medical, Inc.|Endometrial ablation apparatus and method|
    US5433216A|1993-06-14|1995-07-18|Mountpelier Investments, S.A.|Intra-abdominal pressure measurement apparatus and method|
    US5398676A|1993-09-30|1995-03-21|Press; Roman J.|Portable emergency respirator|
    US5439441A|1993-10-12|1995-08-08|Snowden-Pencer, Inc.|Surgical insufflation system with improved determination of body cavity pressure|
    DE4402467A1|1994-01-28|1995-08-03|Wolf Gmbh Richard|Insufflation device|
    US5437629A|1994-04-14|1995-08-01|Bei Medical Systems|Fluid delivery system for hysteroscopic endometrial ablation|
    US5891094A|1995-09-07|1999-04-06|Innerdyne, Inc.|System for direct heating of fluid solution in a hollow body organ and methods|
    US5566680A|1995-09-22|1996-10-22|Graphic Controls Corporation|Transducer-tipped intrauterine pressure catheter system|
    US5787892A|1995-12-18|1998-08-04|Dabney; James Conway|Anal orgasm monitor|
    US5925038A|1996-01-19|1999-07-20|Ep Technologies, Inc.|Expandable-collapsible electrode structures for capacitive coupling to tissue|
    US5733230A|1996-02-21|1998-03-31|Sawchuck; Diane J.|Perineometer for domestic use in prevention of urinary incontinence and method of using the same|
    US7604633B2|1996-04-12|2009-10-20|Cytyc Corporation|Moisture transport system for contact electrocoagulation|
    US5769880A|1996-04-12|1998-06-23|Novacept|Moisture transport system for contact electrocoagulation|
    US6813520B2|1996-04-12|2004-11-02|Novacept|Method for ablating and/or coagulating tissue using moisture transport|
    US5984879A|1996-09-03|1999-11-16|Clinical Innovation Associates, Inc.|Intrauterine pressure catheter device|
    US5951497A|1996-09-03|1999-09-14|Clinical Innovation Associates, Inc.|Pressure catheter device with enhanced positioning features|
    US5891134A|1996-09-24|1999-04-06|Goble; Colin|System and method for applying thermal energy to tissue|
    US5910104A|1996-12-26|1999-06-08|Cryogen, Inc.|Cryosurgical probe with disposable sheath|
    US6159160A|1998-03-26|2000-12-12|Ethicon, Inc.|System and method for controlled infusion and pressure monitoring|
    EP1135060A1|1998-12-04|2001-09-26|The Johns Hopkins University|Telemetric in vivo bladder monitoring system|
    US6296639B1|1999-02-12|2001-10-02|Novacept|Apparatuses and methods for interstitial tissue removal|
    US6080118A|1999-02-25|2000-06-27|Blythe; Cleveland|Vaginal probe and method of using same|
    AT383104T|1999-11-10|2008-01-15|Cytyc Surgical Products|SYSTEM FOR FIXING PERFORATIONS IN A BODY CAVITY|
    US8221404B2|2005-03-24|2012-07-17|Arqos Surgical, Inc.|Electrosurgical ablation apparatus and method|
    US6625495B1|2000-08-02|2003-09-23|Medisox Israel Ltd.|Body-cavity probe with body conformable member|
    US6719709B2|2000-08-31|2004-04-13|Abbeymoor Medical, Inc.|Diagnostic urethral assembly and method|
    DE60238178D1|2001-01-16|2010-12-16|Cytyc Surgical Products Palo A|DEVICE AND METHOD FOR TREATING THE VENOUS REFLUX|
    US20020161304A1|2001-04-30|2002-10-31|Eide Per Kristian|Monitoring pressure in a body cavity|
    US7577476B2|2001-10-26|2009-08-18|Athena Feminine Technologies, Inc|System and method for transducing, sensing, or affecting vaginal or body conditions, and/or stimulating perineal musculature and nerves using 2-way wireless communications|
    US6740047B2|2002-01-25|2004-05-25|Harlan K. Holmes|Motility analysis, display, and interpretation system|
    WO2003070091A1|2002-02-22|2003-08-28|Hans Gregersen|Method and apparatus for investigating force-deformation properties in muscles in walls of bodily hollow systems|
    US7147606B1|2002-09-27|2006-12-12|Chang T Debuene|Urinary diagnostic system having a retrievable sensing device|
    US8078274B2|2003-02-21|2011-12-13|Dtherapeutics, Llc|Device, system and method for measuring cross-sectional areas in luminal organs|
    US7112177B2|2003-03-04|2006-09-26|Wolfe Tory Medical, Inc.|Apparatus for monitoring intra-abdominal pressure|
    US20070255167A1|2004-03-01|2007-11-01|Wolfe Tory Medical, Inc.|Apparatus for monitoring intra-abdominal pressure|
    AU2003901057A0|2003-03-10|2003-03-20|Zsolt Balosh|Intra-abdominal urinary catheter pressure monitor|
    US8652089B2|2004-01-19|2014-02-18|Arthrex, Inc.|System for distending body tissue cavities by continuous flow irrigation|
    US7371231B2|2004-02-02|2008-05-13|Boston Scientific Scimed, Inc.|System and method for performing ablation using a balloon|
    US7462157B2|2004-03-15|2008-12-09|Jarrell John F|Method and apparatus for detecting endometriosis|
    US20050240211A1|2004-04-21|2005-10-27|Stefan Sporri|Apparatus and method for selectably treating a fallopian tube|
    US20050283092A1|2004-06-22|2005-12-22|Cedars-Sinai Medical Center|Continuous compartment pressure monitoring device|
    US20050288603A1|2004-06-24|2005-12-29|Goping Ing H F|Method for obtaining and displaying urethral pressure profiles|
    US20080027358A1|2004-06-30|2008-01-31|Ditens A/S|Morphometry of a Bodily Hollow System|
    US7635338B2|2004-07-21|2009-12-22|Sensometrics As|Processing of continuous pressure-related signals derivable from a human or animal body or body cavity: methods, devices and systems|
    US8591464B2|2004-08-27|2013-11-26|Atul Kumar|Low turbulence fluid management system for endoscopic procedures|
    WO2006021880A2|2004-08-27|2006-03-02|Atul Kumar|A tissue cavity distending system with low turbulence|
    US8388570B2|2004-08-27|2013-03-05|Atul Kumar|Controlled tissue cavity distending system with minimal turbulence|
    WO2006024929A2|2004-09-03|2006-03-09|Atul Kumar|An electromagnetically controlled tissue cavity distending system|
    US8491503B2|2004-09-29|2013-07-23|Covidien Lp|Intrauterine pressure catheter interface cable system|
    CA2582614A1|2004-12-03|2006-06-08|Wolfe Tory Medical, Inc.|Pressure and temperature monitoring balloon catheter|
    US7585280B2|2004-12-29|2009-09-08|Codman & Shurtleff, Inc.|System and method for measuring the pressure of a fluid system within a patient|
    NL1028320C2|2005-02-17|2006-08-21|Drs Jan Beute|Measuring device and device for determining the blood flow of the gastrointestinal tract, as well as registering the intestinal peristalsis.|
    US20070060834A1|2005-08-23|2007-03-15|Odland Rick M|Catheter control console|
    US8007449B2|2005-12-20|2011-08-30|Cytyc Corporation|Method and apparatus for uterine cavity length measurement|
    US20080004566A1|2006-06-30|2008-01-03|Dale Sloan|Gastrointestinal insufflation device and method|
    US20080077053A1|2006-09-05|2008-03-27|Lee Brandon Epstein|Method for Vaginal Skin Biomechanical Evaluation|
    AU2007333103A1|2006-12-12|2008-06-19|Cytyc Corporation|Method and apparatus for verifying occlusion of fallopian tubes|
    US7900805B2|2007-01-10|2011-03-08|Ethicon Endo-Surgery, Inc.|Surgical instrument with enhanced battery performance|
    US20080287833A1|2007-05-16|2008-11-20|Semler John R|Method of evaluating gastroparesis using an ingestible capsule|
    US7963929B2|2007-09-21|2011-06-21|Dtherapeutics, Llc|Devices and systems for sizing of a gastric pouch|
    US20090163908A1|2007-12-19|2009-06-25|Maclean Stewart|Vacuum Pre-Check for a Tissue Ablation Device|
    US8372068B2|2008-10-21|2013-02-12|Hermes Innovations, LLC|Tissue ablation systems|
    US20100222708A1|2008-12-19|2010-09-02|Robert Hitchcock|Intra-vaginal sensor to measure pelvic floor loading|
    KR101019583B1|2009-02-16|2011-03-07|신동아|Auto examination apparatus for disc|
    US20100228239A1|2009-03-09|2010-09-09|Cytyc Corporation|Ablation device with suction capability|
    US8343078B2|2009-11-11|2013-01-01|Minerva Surgical, Inc.|Methods for evaluating the integrity of a uterine cavity|WO2009009398A1|2007-07-06|2009-01-15|Tsunami Medtech, Llc|Medical system and method of use|
    US8197470B2|2007-08-23|2012-06-12|Aegea Medical, Inc.|Uterine therapy device and method|
    US8343078B2|2009-11-11|2013-01-01|Minerva Surgical, Inc.|Methods for evaluating the integrity of a uterine cavity|
    US9186208B2|2010-10-19|2015-11-17|Minerva Surgical, Inc.|Systems for endometrial ablation|
    EP2637590A4|2010-11-09|2014-04-16|Aegea Medical Inc|Positioning method and apparatus for delivering vapor to the uterus|
    US9655557B2|2011-02-04|2017-05-23|Minerva Surgical, Inc.|Methods and systems for evaluating the integrity of a uterine cavity|
    US9050103B2|2011-03-25|2015-06-09|Minerva Surgical Inc.|System and method for endometrial ablation|
    US9788890B2|2011-05-06|2017-10-17|Minerva Surgical, Inc.|Methods for evaluating the integrity of a uterine cavity|
    US20170128127A1|2011-05-06|2017-05-11|Minerva Surgical, Inc.|Gynecological treatment methods|
    US9662060B2|2011-10-07|2017-05-30|Aegea Medical Inc.|Integrity testing method and apparatus for delivering vapor to the uterus|
    US10610294B2|2012-04-22|2020-04-07|Newuro, B.V.|Devices and methods for transurethral bladder partitioning|
    US9883906B2|2012-04-22|2018-02-06|Newuro, B.V.|Bladder tissue modification for overactive bladder disorders|
    US9055950B2|2013-03-15|2015-06-16|Chemo S.A. France|Method and system for delivering a tissue treatment using a balloon-catheter system|
    CN106794031B|2014-05-22|2020-03-10|埃杰亚医疗公司|Integrity testing method and apparatus for delivering vapor to uterus|
    US9993290B2|2014-05-22|2018-06-12|Aegea Medical Inc.|Systems and methods for performing endometrial ablation|
    WO2017143343A1|2016-02-19|2017-08-24|Aegea Medical Inc.|Methods and apparatus for determining the integrity of a bodily cavity|
    EP3537997A4|2016-11-14|2020-09-23|Gynion, LLC|System and method for delivering therapeutic agents to the uterine cavity|
    US10213151B2|2017-01-27|2019-02-26|Minerva Surgical, Inc.|Systems and methods for evaluating the integrity of a uterine cavity|
    EP3573560A4|2017-01-27|2020-10-21|Minerva Surgical, Inc.|Systems and methods for evaluating the integrity of a uterine cavity|
    US11020045B2|2017-03-17|2021-06-01|Minerva Surgical, Inc.|Systems and methods for evaluating the integrity of a uterine cavity|
    法律状态:
    2019-01-08| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|
    2019-07-30| B06U| Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure|
    2019-12-03| B07A| Technical examination (opinion): publication of technical examination (opinion)|
    2020-06-09| B09A| Decision: intention to grant|
    2020-11-03| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/11/2010, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    US12/616,318|2009-11-11|
    US12/616,343|US8343078B2|2009-11-11|2009-11-11|Methods for evaluating the integrity of a uterine cavity|
    US12/616,343|2009-11-11|
    US12/616,318|US8394037B2|2009-11-11|2009-11-11|Systems and devices for evaluating the integrity of a uterine cavity|
    PCT/US2010/056414|WO2011060191A1|2009-11-11|2010-11-11|Systems and devices for evaluating the integrity of a uterine cavity|
    [返回顶部]